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Abstract
Personalized, or genomic, medicine entails tailoring pharmacological therapies according to individual genetic variation at
genomic loci encoding proteins in drug-response pathways. It has been previously shown that steady-state mRNA
expression can be used to predict the drug response (i.e., sensitivity or resistance) of non-genotyped mammalian cancer cell
lines to chemotherapeutic agents. In a real-world setting, clinicians would have access to both steady-state expression levels
of patient tissue(s) and a patient’s genotypic profile, and yet the predictive power of transcripts versus markers is not well
understood. We have previously shown that a collection of genotyped and expression-profiled yeast strains can provide a
model for personalized medicine. Here we compare the predictive power of 6,229 steady-state mRNA transcript levels and
2,894 genotyped markers using a pattern recognition algorithm. We were able to predict with over 70% accuracy the drug
sensitivity of 104 individual genotyped yeast strains derived from a cross between a laboratory strain and a wild isolate. We
observe that, independently of drug mechanism of action, both transcripts and markers can accurately predict drug
response. Marker-based prediction is usually more accurate than transcript-based prediction, likely reflecting the genetic
determination of gene expression in this cross.
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Introduction
Realizing the promise of personalized medicine – a rational
approach to tailoring pharmacological therapy to individual
patients – is an area of intense research [1,2]. One of the central
experimental challenges of personalized medicine is to identify
physiological correlates (i.e., biomarkers) of individual genetic
variation that would serve as reliable diagnostic indicators of
(desired) drug response and (undesired) side effects [3–5]. The
most obvious diagnostic indicator of drug response is genetic
variation itself in the form of single-nucleotide polymorphisms
(SNPs), insertions or deletions, or gross chromosomal rearrange-
ments, which can be catalogued by genotyping techniques.
Genetic variation in genes known to modulate drug response in
general, such as the ABC family of xenobiotic transporters, or the
cytochrome P450 detoxification enzymes, has been successfully
correlated to clinical outcomes of drug therapy [6–11]. Addition-
ally, in candidate-gene approaches, polymorphisms in the
molecular targets of drugs (or downstream pathway components)
have also been correlated with clinical outcome in cancer and in
other diseases [12–18].
A complementary diagnostic indicator of drug response is
mRNA expression. This approach is less biased than candidate-
gene approaches because it uses global transcriptional signatures of
cells in the untreated state to predict drug response. Specifically,
previous work, exemplified by Staunton et al., on the NCI-60 panel
– a collection of 60 tumor cells lines of different tissue origins that
has served as the primary cellular model of cancer genomics [19] –
demonstrated that steady-state mRNA expression could be used to
predict the sensitivity of cancer cell lines to anti-neoplastic drugs
[20]. In related work, others have shown that different
physiological correlates besides gene expression, such as protein
abundance, may be used to predict drug response [21,22]. More
recently, studies have exploited a collection of genotyped
mammalian cell lines to interrogate drug response, and others
have performed expression profiling of mammalian cells in
response to drug treatment [14,17,23]. We sought to perform a
drug-response prediction analysis in a well-controlled system. We
have previously studied segregating variation in a panel of 104
genotyped segregants derived from a cross between a laboratory
strain (BY) and a wild isolate (RM) of Saccharomyces cerevisiae [24–
27]. In the present study we compare how well drug response is
predicted by two types of variables—expression and genotype, test
the potential improvement in drug-response prediction by
combining more than one variable type, and evaluate why one
variable type is more predictive than another for a given drug or
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class of drugs. Our approach affords an opportunity to assess the
predictive power of transcripts versus genetic markers in a simple
model system, and may serve as an initial point of departure for
future analogous studies of personalized medicine in humans.
Results
Drug response can be predicted from transcript levels in
untreated cells
We sought to predict the response of each segregant to each
small-molecule perturbagen (drug), or SMP, from patterns of gene
expression measured in a neutral (i.e., SMP-free) medium. We
classified each segregant as sensitive, resistant or partially resistant
to a given SMP according to its final yield in that SMP; 225 SMP
responses were tested (this represents 89 SMPs, with multiple
responses to some SMPs measured at different time points and
concentrations). The gene expression levels of the segregants
classified as sensitive or resistant were used to train a support
vector machine (SVM) [28]. SVMs are very powerful at classifying
multidimensional data, and therefore should give us the ability to
predict both Mendelian and genetically complex SMP responses.
For each SMP, we used a feature selection algorithm within each
fold of the cross-validation approach (see Methods) to rank the
genes according to their individual contribution to the ability to
predict segregant SMP responses. We then trained support vector
classifiers using 1, 10, 50, 100, 200, 500, and 1000 highest ranked
gene(s). The classifiers were used to predict sensitive/resistant
status of segregants not included in the training set using a cross-
validation approach (Methods and Data S1). We found that the
support vector classifier trained on 1000 genes had the greatest
average predictive power, correctly predicting the SMP response
of 69.7% of the segregants on average for the SMPs considered,
although it should be noted that the differences between 50, 100,
200, 500 and 1000 highest ranked genes are negligible (Figure 1).
The prediction accuracy for individual SMPs varied from near
100% to near chance. We compared this classifier to a naı¨ve mode
classifier, using the same cross validation as with the SVM, which
calls all segregants in the test set sensitive or resistant according to
the category that occurs more frequently in the training set (this
provides a better comparison of the predictive value of expression
information than does 50:50 random classification). Taking the
prediction accuracy from the best performing set of features for
each compound, the SVM outperformed the mode classifier on
average (74% vs. 64%) and equaled or outperformed it for all but
one SMP considered (the single instance was well within the
standard deviation of the SVM performance). Instances where the
mode classifier performed well reflect unequal distributions of
sensitive and resistant segregants. Performance was very robust
Figure 1. Summary of marker-based and transcript-based prediction algorithms. Box plots representing the distribution of prediction
accuracies for all SMPs plotted against number of features selected for prediction. (A) Results of marker-based expression. (B) Results of transcript-
based prediction.
doi:10.1371/journal.pone.0006907.g001
Yeast Pharmacogenomics Model
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e6907
when the algorithm employs classifiers trained on the 50 through
1000 most highly ranked genes. Performance decreased slightly for
the classifier with 10 genes, and dropped more appreciably for the
classifier trained using the single most highly ranked gene
(although performance still remained above chance). This decline
in performance is likely due to insufficient or noisy information
when too few genes are used.
Comparison of transcript- and marker-based prediction
of drug response
After demonstrating our ability to predict SMP response using
steady-state expression alone, we sought to compare these results
to prediction based on genotypes. Linkage analysis is dependent
on an association between a genotyped marker and a phenotype,
in our case sensitivity or resistance to an SMP. Any response to an
SMP that significantly links to a marker should therefore be well
predicted by that same marker. We first used a much simpler
algorithm than the one described above, wherein the genotype at
the single most correlated marker was used to predict sensitivity or
resistance. We repeated this process in a leave-one-out fashion for
all classified segregants. Because we are using the most correlated
marker, the response to SMPs exhibiting strong linkage should be
easier to predict than response to SMPs exhibiting weak linkage or
no linkage. On average we correctly predicted SMP response with
69% accuracy, but, as expected, prediction accuracy was good
(75%) when a strong linkage signal was present (lod $4) and poor
(55%) otherwise. When no strong linkage signal was present, the
prediction accuracy was worse than the performance of the mode
classifier, highlighting that in these instances the single most
correlated marker offered almost no information to perform
classification.
We further sought to examine our ability to predict more
complex SMP responses (those without strong linkage results). We
trained support vector classifiers using 1, 10, 50, 100, 200, 500 and
1000 highest ranked marker(s). We found the support vector
classifier trained on the 500 highest-ranked markers to have the
greatest predictive power overall, correctly predicting the SMP
response of 71.7% of the segregants on average for the SMPs
considered (Figure 1). Performance was very robust in the range
of 50–500 highest-ranked markers, but worsened at 1000. A
deterioration in classifier performance when more than 500
markers are considered is a result of classifier overfitting. After
removing two outliers (alpha factor and niguldipine, which each
show linkage with lod .40 and are nearly perfectly predicted
using both transcripts and markers), we correlated prediction
accuracy with linkage (e.g., lod score) when the prediction
algorithm utilizes either the 200 highest-ranked features
(Figure 2) or the single highest-ranked feature (Figure S1).
Figure 2. The relationship between linkage and prediction accuracy. Scatter plot of prediction accuracy (in percent) of (A) transcript-based
prediction or (B) marker-based prediction versus SMP lod score when the 200 best features are selected.
doi:10.1371/journal.pone.0006907.g002
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The correlation between marker-based prediction accuracy and
linkage is modestly positive (r = 0.13) when using 200 features and,
as expected, significantly greater when predicting on the single
best feature alone (r = 0.48).
A direct comparison of transcript-based prediction and marker-
based prediction is presented in Figure 3. For classifiers trained
on feature sets ranging from 1 to 1000 features, we plotted the
maximum prediction accuracies of transcript- and marker-based
prediction for each SMP; more or fewer features are required for
maximum accuracy depending on the SMP. The plot reveals that
both prediction algorithms perform equally well for a large
number of SMPs, but are weakly correlated (r = 0.37) with each
other. This weak correlation suggests that there is non-overlapping
biological information embodied by transcript levels as compared
to genotyped markers. However, some SMP responses (the on-
diagonal points in Figure 3) are equally well predicted by
transcripts and by markers, demonstrating that both are providing
equivalent amounts of information. It is possible that the
information being provided by the two sets of predictors is
redundant, resulting from the fact that expression differences
among the segregants arise due to the underlying genetic variation.
For example, consider the response to the SMP alpha factor.
Alpha factor is a 13 amino acid pheromone secreted by yeast cells
of the alpha mating type in the presence of yeast cells of the
opposite a mating type; a cells arrest in the presence of alpha
factor because they express the sensitizing alpha-factor receptor
STE2. Genotype at the mating type locus and expression of STE2
are completely redundant in this case where sensitivity is
determined by the presence or absence of the drug target. A
clinical analogy would be clinical efficaciousness of EGF-receptor
antagonists (e.g., gefitinib) in the 10% of patients with lung cancers
that express sensitizing alleles (somatic deletions and point
mutations) of the EGF receptor [29]. Genotyping the EGF
receptor stratified patients into drug-responsive and drug-unre-
sponsive cohorts, and EGF receptor expression levels correlate
with drug sensitivity.
22 SMPs are better predicted (.15% percent improvement) by
markers than transcripts, while no SMPs are better predicted by
transcripts than markers by the same margin. In fact, only 6 SMPs
are better predicted by transcripts than markers by 10%, and of
these none by greater than 12.2% (Figure 3; Figure S1). One
SMP for which genotype is much more predictive is tetrachlor-
oisophthalonitrile, an uncoupler of oxidative phosphorylation. The
maximum predictive power of expression for tetrachloroisophtha-
lonitrile is 65% considering the 500 most predictive transcripts,
while the maximum predictive power of genotype is 90%
considering only the single most strongly linked genetic marker.
In previous work we showed that a non-synonymous mutation in
the gene PHO84, which encodes a high-affinity inorganic
phosphate transporter, alters sensitivity to tetrachloroisophthalo-
nitrile [27]. We also showed that the quantitative trait locus (QTL)
on chromosome 13 that contains PHO84 is a linkage hot spot that
Figure 3. Head-to-head comparison of marker-based prediction and transcript-based prediction. Plotted are maximum predictive
accuracies (in percent) of transcript-based prediction (y-axis) versus marker-based prediction (x-axis). Regression line is solid black; the diagonal (x = y)
is dashed black; red points denote SMPs described in the main text as that are well predicted by genotype but poorly predicted by expression.
doi:10.1371/journal.pone.0006907.g003
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affects response to 25 SMPs [27]. The above-mentioned SNP in
PHO84 also alters to a lesser extent sensitivity to the chemically
similar SMP pentachlorophenol, which suggests that greater
genetic complexity underlies the physiological response of cells
to pentachlorophenol. The maximum predictive accuracy of
expression for pentachlorophenol is 69% considering the 500 most
predictive transcripts, while the maximum predictive power of
genotype for it is 90% considering the single most linked genetic
marker. Another example of more accurate genotype-based
prediction is response to copper sulfate (CuS04). The maximum
predictive power of expression for copper sulfate is 58%
considering the 10 most predictive transcripts, while the maximum
predictive power of genotype is 93% considering only the single
most linked genetic marker. Linkage analysis has shown that a
marker near CUP1, which encodes a copper-binding protein that
mediates resistance to copper stress, segregates with copper sulfate
resistance; CUP1 is also subject to copy-number variation between
strains [27]. The inability of transcripts to predict SMP response
may occur when genetic variation does not perturb expression
levels under neutral (drug-free) conditions, especially in the case of
stress-responsive genes, and therefore does not manifest a steady-
state expression signature that would enable transcript-based
prediction.
Next we considered cases where transcript-based prediction out-
performs marker-based prediction. Expression outperforms geno-
type for 80 SMP response predictions above the diagonal in
Figure 3. This improvement may be due to chance or to
expression signatures caused by genetic factors. However, as
mentioned above, there are no SMP responses for which
expression-based prediction is 15% more accurate than geno-
type-based prediction (Figure 3). This result is consistent with
expectation given that expression differences are ultimately
explained by genetic differences in these yeast strains. However,
there are 6 SMP responses where expression-based prediction
outperforms marker-based prediction by 10% or more. In these
cases, expression may be a better predictor of SMP response than
genotype because several unlinked polymorphisms, possibly in
transcriptional regulatory genes, could affect steady-state expres-
sion of multiple genes in the pathway modulated by the SMP.
Additionally, in cases where transcript-based prediction outper-
forms marker-based prediction by at least 10%, the average LOD
score is 5, while in the reverse case it is 8.5. This is consistent with
the idea that transcripts may be valuable when sensitivity or
resistance has a complex genetic basis with many minor-effect
variants rather than one major-effect variant.
Using both transcript and marker data improves
prediction ability for SMPs
We next asked whether combining both transcripts and markers
into a single prediction algorithm would improve our ability to
predict SMP response. First, we looked at the best prediction
accuracy across all feature sets of both marker- and transcript-
based prediction. In 80 out of 226 SMP responses tested, the best
transcript-based prediction outperformed the best marker-based
prediction, with an average improvement in accuracy of 4.8%.
Interestingly, there are no distinguishing mechanistic characteris-
tics of this group of 60 SMP responses, (which, in some cases,
includes the same compound tested at multiple concentrations or
at multiple time points); in other words, they are structurally
diverse and target a wide array of cellular processes. This suggests
that transcript information can provide additional predictive
information above genotype data alone.
As a second test, we created a combined set of features that
included all transcripts and markers, totaling over 9,000 features.
We repeated the above-described process of selecting the best 1,
10, 50, 100, 200, 500 and 1000 features, and then used them to
train a support vector classifier. The set of 500 features performed
best on average with an accuracy of 72%, essentially the same as
the marker-based prediction using the same number of features
(71.6%). Interestingly, genotyped markers comprised over 95% of
all selected features, with many (60) SMP response predictions
based solely on marker features. These results are consistent with
the observation that genotyped markers provide most of the
information used in SMP response prediction. However, when
transcripts are selected, they often encode gene products involved
in biological processes affected by the SMP. For example,
carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) is a
proton ionophore that depolymerizes the mitochondrial mem-
brane potential [30]. At least three QTL determine drug response
to FCCP in this cross [27]. Expression of two genes, one encoding
a component of the vacuolar ATPase (YDL185W) and the other a
component of the F1-F0 ATP synthase (YMR064W), improves
FCCP response prediction. The differing information provided by
the best combined set of features versus the best set of markers
suggests that valuable insight may be gained from using both
steady-state transcript levels and genotyped markers. However,
combining both transcripts and markers into a single set of features
rarely performs better than taking the best of marker-only or
transcript-only prediction accuracy, possibly due to the added
noise of too large a set of features.
Discussion
We and others have previously shown that naturally recombi-
nant yeast strains provide a model for the study of therapeutically
relevant complex traits (i.e., small-molecule drug response)
[26,27,31]. Here we have shown that in addition to serving as a
model for complex traits a panel of 104 genotyped and expression-
profiled yeast strains may also serve as a model for personalized
medicine. In the present study, we used a pattern recognition
algorithm to accurately predict the sensitivity to small molecules of
individual segregants from both steady-state transcript levels in
untreated cells and genotyped markers. We observed that markers
are slightly more predictive overall, but much better in a few cases.
For example, resistance to polychlorinated phenols due to a
polymorphism in the high-affinity inorganic phosphate transporter
PHO84 is poorly predicted by transcripts but accurately predicted
by markers. It should be noted that we predicted compound
response from steady-state mRNA expression levels not only when
inheritance of both compound response and expression levels is
Mendelian, but also in cases when inheritance of both compound
response and expression levels is genetically complex. Moreover,
we accurately predicted SMP response in cases when there existed
strong linkage between a marker and SMP response (lod .4) as
well as when no strong linkage was present (lod , 4).
Transcript-based prediction performs similarly to marker-based
prediction for most SMP responses, and thus expression profiles
provide a useful proxy when genotypes are not available.
Expression may sometimes be a better predictor of compound
response than genotype because expression can integrate many
genetic changes, and may therefore reflect the overall physiological
state of the cell rather than just the effect of one locus. On the
other hand, expression may be a poorer predictor of compound
response than genotype in cases when transcript levels of untreated
cells is uncorrelated to transcript levels of drug-treated cells. Gene
expression may capture the same information as genotypes for
several reasons. First, a polymorphism may affect both gene
expression and compound response independently (pleiotropy),
Yeast Pharmacogenomics Model
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with the expression levels providing a read-out of the inheritance
at the locus. Second, a polymorphism that affects compound
response may be linked to a different polymorphism that affects
gene expression. The third and most interesting case involves
polymorphisms that affect the expression of drug targets or other
genes that function in the pathways that are involved in SMP
response; in this case the expression changes provide direct
functional information. Further functional studies are needed to
distinguish these possibilities and quantify the prevalence of each.
We observed that expression provided little predictive power
over genotype alone. In our system, genotype largely determines
both expression levels and drug response; environmental condi-
tions were kept constant during expression experiments, and only
differed on the basis of SMP treatment in drug response
experiments. We expect that gene expression will provide
considerable additional predictive power when environmental
variation is present, for example in human patients who will differ
in diet, drugs taken, and other factors. This study demonstrates the
benefit of having multiple sources of data in understanding
complex pharmacogenomic traits.
Methods
Chemoprediction algorithm
Segregants were classified as sensitive or resistant based on the
standard deviation from zero of each segregant’s six replicate
growth values. If a segregant’s average growth rate in the presence
of a given SMP was at least one standard deviation below zero it
was considered sensitive to that SMP; if the average growth rate
was a standard deviation or more above zero it was considered
resistant. Segregants with standard-deviation ranges overlapping
zero were not classified, and were removed from the analysis.
Segregant growth rates at various time points were available for
some of the 92 SMPs surveyed, providing a total of 333 sets of
segregant growth rates. To be able to determine a pattern between
gene expression and sensitivity or resistance to a given SMP, a
sufficient number of ‘‘sensitive’’ and ‘‘resistant’’ segregants are
needed. Therefore only growth rate sets with at least 10 sensitive
and 10 resistant segregants were treated, eliminating 107 growth
rate sets.
Before applying the prediction algorithm, we reduced noise in
the data by ranking each of the segregants’ genes’ association with
drug sensitivity. For each of the 226 sets considered, a stratified 10-
fold cross-validation scheme was used to select features and train
support vector classifiers, and to test the classifiers. This involves
random division of the data into ten similarly sized parts, each
with a classification profile (in this case, the ratio of sensitive to
resistant segregants) approximately representative of the full data
set; one part is kept aside for testing the classifier, and the
remaining nine subsets are used for feature selection and then
training; the full selection/training/testing process is carried out
ten times using a different portion of data for testing each time.
Feature selection – in our case selecting the most relevant genes for
segregant response to an SMP – was performed to reduce noise in
the data and hopefully make any pattern more readily identifiable.
The feature selection algorithm, performed within each fold of the
cross-validation scheme, used a support vector machine (SVM)
[28], a pattern-recognition or machine-learning algorithm, to
weight each gene according to the strength of its relationship with
the segregants’ sensitivity/resistance to the SMP. (Note that this
SVM is independent of the support vector classifier described
below, which we use in the second stage of prediction.) The
features were then ranked according to the square of the weight
assigned by the SVM, with the greatest square ranked highest, and
only a specified number of the top-most genes were used for
training. Sequential minimal optimization (SMO) [32–34] with an
RBF kernel, a machine-learning algorithm, was used to train a
support vector classifier. For each run through the 10-fold cross-
validation, the SMO parameters were optimized and then applied
to the segregants’ chemosensitivity classification and the selected
gene expression data. The classifier was then used to predict the
chemosensitivity of each segregant in the test portion, and the
results were compared with the actual chemosensitivity to
determine classifier performance for that run. The entire process
is repeated until each of the 10 subsets has been used for testing.
The accuracy quoted is the percent of correctly classed instances in
the test portion averaged over all ten runs. Support vector
classifiers were trained using the 1, 10, 50, 100, 200, 500 and 1000
highest ranked gene(s). Computation for the training, testing and
analysis was carried out using algorithms from Weka (Waikato
Environment for Knowledge Analysis) [35] and the Java
programming language.
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